0%, 100%, then 200%: How Trump’s new generic drug tariff plan could hit India

Donald Trump announced phased tariffs on imported generic medicines starting August 2026. These tariffs will gradually increase to 200 percent over three years. This policy aims to reshore pharmaceutical production back into America. India, a major supplier of affordable generics, faces significant impact from these changes. The move adds uncertainty to ongoing bilateral trade agreement.